This bill establishes a new section in Florida law, specifically section 499.0296, which focuses on the treatment of chronic and terminal illnesses. It defines key terms such as "chronically ill patient" and "terminally ill patient," outlining the rights of these patients to determine their treatment courses with the assistance of healthcare providers. The bill authorizes compounding pharmacies to obtain specific active pharmaceutical ingredients necessary for individualized treatment plans, provided these ingredients meet certain quality and safety standards.

Additionally, the bill stipulates that compounding pharmacies can source active pharmaceutical ingredients that lack a monograph from recognized pharmacopoeias, as long as they are obtained from FDA-registered manufacturers and comply with state laws. It explicitly prohibits any treatment intended to cause a patient's death, ensuring that the focus remains on providing supportive care for those with chronic or terminal conditions. The act is set to take effect on July 1, 2025.